Trends and predictors of mother-to-child transmission of HIV in an era of protocol changes: Findings from two large health facilities in North East Nigeria

Ademola Joshua Itiola1*, Ameena Ebrahim Goga2,3,4, Vundli Ramokolo2

1 School of Public Health, University of the Western Cape, Bellville, Cape Town, South Africa, 2 Health Systems Research Unit, South African Medical Research Council, Pretoria, South Africa, 3 HIV Prevention Research Unit, South African Medical Research Council, Pretoria, South Africa, 4 Department of Paediatrics, University of Pretoria, Pretoria, South Africa

* ademola.itiola@gmail.com

Abstract

Background

Research studies have demonstrated a reduction in the risk of mother-to-child transmission of HIV (MTCT) to less than 2%, or 5% in non-breastfeeding and breastfeeding populations, respectively, with antiretroviral interventions. However, the risk of MTCT in routine health-facility settings, where service delivery is usually sub-optimal needs monitoring.

Method

We conducted a retrospective review of data from 2008–2014, in two health facilities in Adamawa State, Nigeria. Descriptive statistics were used to estimate overall MTCT rate and MTCT rate by year, and period of prevention of mother-to-child transmission of HIV (PMTCT) protocol implementation. We conducted simple and multiple logistic-regression analyses, to identify predictors of MTCT.

Results

Data from 1,651 mother-to-infant pairs, with HIV deoxyribonucleic acid (DNA) polymerase-chain reaction (PCR) test results from 2008 (n = 49), 2009 (n = 246), 2010 (n = 280), 2011 (n = 335), 2012 (n = 290), 2013 (n = 225) and 2014 (n = 226) were analysed. The overall MTCT rate among HIV exposed infants (HEIs) was 9.7% (95% CI 8.3% - 11.1%) at a median age of 8 weeks (IQR = 6–20). The MTCT rate decreased from 14.3% (4.4%-24.2%) in 2008 to 4.9% (2.1%-7.7%) in 2014 (p = 0.016). The MTCT rate was the lowest (5.4% [3.7% - 7.0%]) when all pregnant women living with HIV received triple antiretroviral therapy, as treatment or prophylaxis (ARVT/P). Using the pooled data, we found that infant age, breastfeeding option, antiretroviral regimen and year were predictors of MTCT. The adjusted odds of MTCT were significantly higher, when neither mother nor HEI received...
Conclusion

The MTCT rate declined significantly between 2008 and 2014 in these two routine health-facility settings in Nigeria. Our study suggests that ARVT/P yields the lowest MTCT. Thus, efforts to scale up lifelong ARVT/P (Option B+) in Nigeria should be accelerated.

Introduction

By 2015, Nigeria had the highest number of children living with HIV globally, estimated at 260,000 [1, 2]. Almost a fifth of these children (41,000) were newly infected with HIV in 2015, representing 27% of the global new pediatric HIV infections for the year [1]. Approximately 2.2 million children in Nigeria have been orphaned by HIV/AIDS [3]. To prevent mother-to-child transmission of HIV (MTCT), Nigeria implemented the prevention of mother-to-child transmission of HIV (PMTCT) programme in 2002, in six health facilities [4]. By 2014, the programme had been scaled up to 6000 facilities, which represents approximately 18% of the health facilities in Nigeria [5, 6, 7]. The adult HIV prevalence in Nigeria is estimated to be 1.4%, as of 2018, with an antenatal HIV prevalence of 2.9% in 2014 [8, 9].

As recommended by the World Health Organization (WHO), Nigeria implements a comprehensive 4-pronged strategy to prevent HIV/AIDS in infants and children [3, 10]. The first PMTCT guideline in Nigeria was produced in 2001; and it was updated in 2005, 2007, 2010, 2014 and 2016 [4, 11]. Both the eligibility criteria and the recommended antiretroviral drugs (ARVs) changed with each revision—from zidovudine during pregnancy— to triple ARV therapy during pregnancy, as treatment or prophylaxis (ARVT/P) by 2010 to ART during pregnancy by 2014, S1 Table [3, 11, 12].

Despite the implementation of the PMTCT programme in Adamawa State, Nigeria; since September 2007, no study has been conducted to investigate PMTCT effectiveness. To date, the only country-level findings available in Nigeria are from operational research conducted in 2005, when only 11 tertiary sites offered PMTCT services [4]. Most of the facility-based PMTCT effectiveness studies in Nigeria were single-site studies conducted at tertiary or teaching hospitals [13–18]. Most published Nigerian studies also reported findings during one period of the PMTCT protocol [13, 14, 19–24]. Although a review by Khamofu et al., (2015) reported MTCT rates from 2008–2014. This study did not aggregate MTCT rates by PMTCT protocol period [6]. Additionally, the study did not report age of testing, confidence intervals of MTCT rates or predictors of MTCT [6].

We, therefore, conducted a study to evaluate PMTCT effectiveness in two health facilities in Adamawa State, Nigeria over a 7-year period (2008–2014) of PMTCT programme implementation. This represents two periods of PMTCT protocol changes (2007 and 2010), as well as a transitional period, during which both the 2007 and the 2010 PMTCT guidelines were implemented. Additionally, we report predictors of MTCT using the pooled data, controlling for year.

Methodology

We conducted a retrospective review of routine facility-held records; and analyzed routine individual-level patient data extracted from facility-based registers, from January 2008 to
December 2014 (S1 File). All data were analyzed cross-sectionally. Records reviewed included those from early-infant diagnosis (EID)/Infant follow-up registers and HIV PCR request/result forms accessed from the PMTCT and medical record units of the hospitals. The review was conducted at Specialist Hospital (SH) Yola, a health facility providing predominantly secondary healthcare services in the Yola North Local Government Area (LGA), and Federal Medical Centre (FMC) Yola, a tertiary health facility in the Yola South LGA. The two health facilities commenced delivery of PMTCT services in September 2007 and January 2008, respectively. Other services rendered by both of these facilities included antenatal care (ANC), general outpatient and specialist services.

The facilities render services to pregnant women and HIV-exposed infants (HEIs), in accordance with national cascades and protocols (S1 Fig and S1 Table). Using Laseq DBS Collection kits with 5 spots, infant dried blood spot (DBS) samples were collected and couriered to the Federal Medical Centre, Jalingo. This centralized HIV deoxyribonucleic acid polymerase-chain reaction (DNA PCR) testing facility uses the Roche brand of PCR machine; and is located approximately 167 kilometres away from Yola.

**Definitions**

We defined MTCT rate as the proportion of tested HIV-exposed infants (HEIs) who tested HIV positive. This formed the basis of our evaluation of PMTCT effectiveness as it allowed us to assess MTCT reduction in routine health-facility settings.

For the overall MTCT rate, the MTCT rate by year, and the MTCT rate by PMTCT protocol period, the denominators were the total number of HEIs tested for HIV, with DNA PCR results: for the entire seven-year period, during a specific year, and during the specific protocol period; while the numerators were the number of HEIs that tested HIV positive: for the entire seven-year period, during a specific year, and during the specific period.

We defined Period 1, as the period when only the 2007 National Guidelines were used (Jan 2008 –Jan 2010), and Period 2 as the period when only the 2010 National Guidelines were used (Jun 2012–Dec 2014). The transitional period refers to the period when both the 2007 and the 2010 Guidelines were used (Feb 2010 –May 2012). We reviewed regimens taken by HIV-positive pregnant women and HEIs, in order to confirm the duration of the transition period. From the pooled data, we estimated the transitional period to be two years and four months (Feb 2010 –May 2012).

We defined exclusive breastfeeding as feeding an infant with breast milk only [25]. This excluded the use of formula feed, or any other liquids or solids [25]. The use of the prescribed medications and oral rehydration salt (ORS) for diarrhea was, allowed, as per WHO definitions [25]. We defined mixed feeding as feeding an infant with both breast milk and formula feed, or any other liquid, or solids [25]. Lastly, replacement feeding/not breastfed at all, refers to avoiding all breastmilk and feeding an infant with an appropriate replacement milk [25].

**Data analysis**

The data were analyzed by using STATA 14.2 [26]. Descriptive statistics (proportions) were used to describe the overall MTCT rate, MTCT rate by year, and the PMTCT protocol periods. Simple and multiple logistic regression analyses were conducted to establish the predictors of MTCT. Covariates were selected, based on the current literature on the risk factors for MTCT [19,21, 23, 24, 27–29]. Specifically, we included gender, infant age, breastfeeding option, ART/ARV prophylaxis receipt, hospital and year, in our logistic regression model. A p-value <0.05 was considered statistically significant. No adjustment was made in estimating the confidence intervals.
Data management
All 158 infants, without first HIV DNA PCR test results, were excluded from all analyses. HIV-exposed infants excluded from the analyses differed significantly by age and feeding option, as well as by infant and maternal ARV use, compared with HEIs included in the analyses (S2 Table). For longitudinally linked results, if an infant tested HIV negative at first test and HIV positive at second testing, the HIV positive result was used in the analysis.

Ethics approval
Ethics approval for the study was obtained from the Senate Research Committee of the University of the Western Cape. Permission to access patient records was obtained from the research ethics committees of the two health facilities involved in this study, and from the Adamawa State Ministry of Health (SMoH). No individual patient-level consent was obtained; as no patient was interviewed. All data were de-identified: names of patients were not extracted. Individual patient-level consent was not required by the ethics review committees.

Results
Data on 1,651 HEIs were included in the analyses (Fig 1). As shown in Table 1, more than half of the babies were males (51.3%); and only 30.2% of the babies were tested for HIV by the recommended age of 6 weeks. The commonest mode of feeding adopted by mothers at the time the infant was brought for HIV testing (median age of 8 weeks) was exclusive breastfeeding (53.9%); while mixed feeding (15.6%) was the least common for the entire 7 years under review.

Overall MTCT rate and MTCT rate by year
The overall MTCT rate for all HEIs with first HIV DNA PCR test result, between 2008 and 2014 was 9.7% [160/1,651] (95% CI 8.3% - 11.1%) at a median age of 8 weeks (IQR = 6–20), with no statistically significant difference between the two sites. (95% CI of the rate difference = -4.4% - 1.2%; p = 0.273). Except for the increase seen between 2008–9 (from 14.3% [7/49] in 2008 to 17.9% [44/246] in 2009) and between 2012–13 (from 5.2% [15/290] in 2012 to 6.2% [14/225] in 2013), the MTCT rate generally declined over the 7-year period (Table 2); and this decline was statistically significant (p = 0.016).

MTCT rate by PMTCT protocol periods
The lowest MTCT rate was in Period 2 (5.4% [39/726] (3.7%-7.0%)); while the highest was in Period 1 (16.4% [58/353] (12.6%-20.3%)), Table 3. The decline between Period 1 and Period 2 was statistically significant (p = 0.000).

Predictors of MTCT
Multiple regression analysis revealed that infant age, breastfeeding option, antiretroviral regimen and year predicted MTCT. HEIs older than 12 months had 3.3 times (adjusted odds ratio (AOR)), the odds of being HIV positive than those ≤6 weeks; while mixed fed infants had 2.4 times the odds of being HIV positive than infants that were not breastfed. The odds of infant HIV positivity was also higher (AOR = 26.4), when neither the mother, nor the infant received prophylaxis. HEIs born in 2012 had lower odds of being HIV positive than those born in 2008 (Table 4).
Discussion

Using routine data (2008–2014) from two health facilities, we demonstrated a decline in MTCT rate with improvements in the PMTCT protocol. Overall, the MTCT rate was 9.7% with a declining trend from 14.3% in 2008, to 4.9% in 2014 (p = 0.016). The MTCT rate was lowest (5.4%) during the period when Option B was in use for ARVT/P. Infant age, breastfeeding option, antiretroviral regimen and year were significant risk factors for MTCT.

The MTCT rate of 22.0% and 22.5% from studies conducted by Afe et al., (2011) and Audu et al. (2014) using data gathered between February 2007 and October 2008 at six health facilities (each) in Lagos State, Nigeria fell within our confidence intervals for 2008 (14.3% (95%CI 4.4% - 24.2%)) [19,20]. Our overall MTCT rate estimate of 11.25%, using pooled data from 2008–2012 was very close to the MTCT rate of 11.0% at 17 weeks, found in four secondary health facilities in Kwara and Niger States, Nigeria, 2009–2012 [30]. It was also close to the MTCT rate of 9.8% (mean age = 17.83 weeks) reported by Inalegwu et al. (2016), who analysed data of the first HIV DNA PCR test results from 150 health facilities, 2008–2012 [31]. Our point estimate of 4.9% in 2014 is lower than the 6.0% reported by Khamofu et al. (2015), and 13.0% at 6 weeks, projected for Nigeria by UNAIDS [6, 32]. Modelled data suggest that between 2009 and 2015, new HIV infections among children in Nigeria declined by 21% [32]. This progress is, however, judged to be slow; as Nigeria and Angola are the only two countries with less than 33% reduction in new HIV infections among children [32].

We observed a general decline in MTCT rate, with the introduction of more efficacious regimen [3,11,12] with the lowest MTCT rate of 5.4% during the period when the triple regimen was in use for ARVT/P. We also noted lower odds of being HIV positive in 2012 compared to 2008 in the adjusted analysis. These findings further buttressed the need for countries to adopt...
Table 1. Baseline characteristics and prophylaxis status for HIV exposed infants (2008–2014) (N = 1,651).

| Variable                      | FMC Yola | SH Yola | Total   |
|-------------------------------|----------|---------|---------|
|                               | n (%)    | n (%)   | n (%)   |
| **Gender**                    |          |         |         |
| Male                          | 383 (51.3%) | 453 (50.1%) | 836 (50.6%) |
| Female                        | 363 (48.7%) | 452 (49.9%) | 815 (49.4%) |
| Total                         | 746 (100.0%) | 905 (100.0%) | 1,651 (100.0%) |
| **Age**                       |          |         |         |
| ≤6 weeks                      | 276 (37.0%) | 233 (24.6%) | 499 (30.2%) |
| >6 weeks to 2 months          | 148 (19.8%) | 239 (26.4%) | 387 (23.4%) |
| >2 months– 6 months           | 184 (24.7%) | 257 (28.4%) | 441 (26.7%) |
| >6–12 months                  | 106 (14.2%) | 139 (15.4%) | 245 (14.8%) |
| >12 months                    | 25 (3.4%) | 34 (3.8%) | 59 (3.6%) |
| Missing                       | 7 (0.9%) | 13 (1.4%) | 20 (1.2%) |
| Total                         | 746 (100.0%) | 905 (100.0%) | 1,651 (100.0%) |
| **Infant-Feeding Option**     |          |         |         |
| Exclusive breastfeeding       | 381 (51.1%) | 509 (56.2%) | 890 (53.9%) |
| Not breastfed, or Replacement feeding | 252 (33.8%) | 177 (19.6%) | 429 (26.0%) |
| Mixed feeding                 | 70 (9.4%) | 187 (20.7%) | 257 (15.6%) |
| Missing                       | 43 (5.8%) | 32 (3.5%) | 75 (4.5%) |
| Total                         | 746 (100.0%) | 905 (100.0%) | 1,651 (100.0%) |
| **Reason for PCR**            |          |         |         |
| First test for healthy exposed infant | 578 (77.5%) | 707 (78.1%) | 1,285 (77.8%) |
| First test for sick infant    | 18 (2.4%) | 12 (1.3%) | 30 (1.8%) |
| Problem with first test       | 150 (20.1%) | 186 (20.6%) | 336 (20.4%) |
| Total                         | 746 (100.0%) | 905 (100.0%) | 1,651 (100.0%) |
| **Maternal ARVs**             |          |         |         |
| ART                           | 417 (55.9%) | 179 (19.8%) | 596 (36.1%) |
| ARVP                          | 182 (24.4%) | 177 (19.6%) | 359 (21.7%) |
| ‘ART or Triple Regimen        | 42 (5.6%) | 149 (16.5%) | 191 (11.6%) |
| None                          | 87 (11.7%) | 130 (14.4%) | 217 (13.1%) |
| Missing                       | 18 (2.4%) | 270 (29.8%) | 288 (17.4%) |
| Total                         | 746 (100.0%) | 905 (100.0%) | 1,651 (100.0%) |
| **Type of Maternal ARVP**     |          |         |         |
| AZT + 3TC and sdNVP           | 134 (73.6%) | 44 (24.9%) | 178 (49.6%) |
| AZT and sdNVP in labour       | 8 (4.4%) | 27 (15.3%) | 35 (9.7%) |
| Triple regimen                | 35 (19.2%) | 81 (45.8%) | 116 (32.3%) |
| sdNVP                         | 3 (1.6%) | 19 (10.7%) | 22 (6.1%) |
| Unknown                       | 2 (1.1%) | 1 (0.6%) | 3 (0.8%) |
| Missing                       | 0 (0.0%) | 5 (2.8%) | 5 (1.4%) |
| Total                         | 182 (100.0%) | 177 (100.0%) | 359 (100.0%) |
| **Infant ARVs**               |          |         |         |
| sdNVP at birth                | 35 (4.7%) | 0 (0.0%) | 35 (2.1%) |
| sdNVP at birth and AZT for 4 weeks | 252 (33.8%) | 132 (14.6%) | 384 (23.3%) |
| NVP for 6 weeks               | 321 (43.0%) | 346 (38.2%) | 667 (40.4%) |
| Unknown                       | 3 (0.4%) | 0 (0.0%) | 3 (0.2%) |
| None                          | 109 (14.6%) | 161 (17.8%) | 270 (16.4%) |
| Missing (ARV Type)            | 5 (0.7%) | 4 (0.4%) | 9 (0.5%) |
| Missing (Prophylaxis use)     | 21 (2.8%) | 262 (29.0%) | 283 (17.1%) |
| Total                         | 746 (100.0%) | 905 (100.0%) | 1,651 (100.0%) |

N = Total number of HIV-Exposed Infants

*Pregnant women took triple regimen, either solely for PMTCT (ARVP), or as ART (both for PMTCT and their health). Documentation was not strong enough to clearly delineate as ART, or ARVP.

https://doi.org/10.1371/journal.pone.0224670.t001
either Option B or Option B+ as the preferred PMTCT regimen. While it is commendable that Nigeria adopted Option B+ in June 2016 [32] the country will only be able to achieve virtual elimination of MTCT (reduction of MTCT risk to < 5%) if the coverage of ARVT/P, which stood at 30% by 2016, can be improved [6, 32]. Additionally, intensified training and monitoring is required to ensure prompt migration to the new protocol, given that prescribing habit would not necessarily change immediately. The country would also need to implement strategies to ensure adherence as there are concerns that asymptomatic pregnant women living with HIV, who do not necessarily require ART for their health, could discontinue treatment; and they would be ultimately lost to follow up [33, 34]. A study conducted in Haiti reported higher attrition among pregnant women living with HIV initiated on ART under Option B+ compared to non-pregnant women on ART; while a readiness assessment conducted by Erekaha et al. in North-Central Nigeria suggested that some pregnant women living with HIV would only take medication to protect their babies; and they might well stop after delivery [33, 34].

As reported in other studies conducted in Africa, not all mother-infant pairs in our study received antiretroviral drugs, despite the availability of these interventions [35,36]. Measures must therefore be implemented to improve the utilization of PMTCT services.

The higher odds of MTCT among infants older than 12 months could be attributed to postnatal MTCT because of prolonged breastfeeding. A higher proportion of mother-infant pairs

### Table 2. Yearly trend of MTCT rate for FMC Yola and SH Yola at median age of 8 weeks (N = 1651).

| Year   | FMC Yola          | SH Yola          | Total          |
|--------|-------------------|-----------------|----------------|
|        | Number HIV positive (%) | 95% CI of the % | Number HIV positive (%) | 95% CI of the % | Number HIV positive (%) | 95% CI of the % |
| 2008   | 2 (14.3%)         | 0.0%-33.3%      | 5 (14.3%)      | 2.5%-26.1%      | 7 (14.3%)        | 4.4%-24.2%      |
| 2009   | 14 (13.3%)        | 6.8%-19.9%      | 30 (21.3%)     | 14.5%-28.1%     | 44 (17.9%)       | 13.1%-22.7%     |
| 2010   | 16 (11.3%)        | 6%-16.5%        | 22 (15.9%)     | 9.8%-22.1%      | 38 (13.6%)       | 9.5%-17.6%      |
| 2011   | 17 (9.4%)         | 5.1%-13.7%      | 14 (9.1%)      | 4.5%-13.6%      | 31 (9.3%)        | 6.1%-12.4%      |
| 2012   | 4 (3.8%)          | 0.1%-7.4%       | 11 (6.0%)      | 2.5%-9.4%       | 15 (5.2%)        | 2.6%-7.7%       |
| 2013   | 5 (5.6%)          | 0.8%-10.3%      | 9 (6.7%)       | 2.4%-10.9%      | 14 (6.2%)        | 3.1%-9.4%       |
| 2014   | 8 (7.4%)          | 2.4%-12.4%      | 3 (2.5%)       | *0.0%-5.4%      | 11 (4.9%)        | 2.1%-7.7%       |
| Overall | 66 (8.8%)         | 6.8%-10.9%      | 94 (10.4%)     | 8.4%-12.4%      | 160 (9.7%)       | 8.3%-11.1%      |

N = Total number of HIV Exposed Infants
* The confidence limit was amended, so that the confidence intervals were bounded between 0 and 100%.

https://doi.org/10.1371/journal.pone.0224670.t002

### Table 3. MTCT rate by periods of PMTCT protocol at median age of 8 weeks (N = 1651).

| PMTCT Period       | FMC Yola          | SH Yola          | Total          |
|--------------------|-------------------|-----------------|----------------|
|                    | Number HIV positive (%) | 95% CI of the % | Number HIV positive (%) | 95% CI of the % | Number HIV positive (%) | 95% CI of the % |
| Period 1 (Jan 2008 –Jan 2010) | 20 (12.5%) | 7.4%-17.6% | 38 (19.7%) | 14.1%-25.3% | 58 (16.4%) | 12.6%-20.3% |
| Transitional Period (Feb 2010 –May 2012) | 30 (9.5%) | 6.3%-12.7% | 33 (12.8%) | 8.7%-16.9% | 63 (11.0%) | 8.4%-13.6% |
| Period 2 (Jun 2012-Dec 2014) | 16 (5.9%) | 3.1%-8.7% | 23 (5.1%) | 3.0%-7.1% | 39 (5.4%) | 3.7%-7.0% |
| Total              | 66 (8.8%)         | 6.8%-10.9%      | 94 (10.4%)     | 8.4%-12.4%      | 160 (9.7%)       | 8.3%-11.1%      |

**Period 1 PMTCT regimen:** Mother: Ante partum—AZT from 28 weeks of gestation or AZT+3TC from 34–36 weeks of gestation; Intrapartum—sdNVP +AZT+3TC at onset of labour; Postpartum—AZT+3TC for 7 days Infants: sdNVP at birth (preferably within 72 hours) plus AZT for 6 weeks. **Period 2 PMTCT regimen:** Mother: AZT + 3TC + (EFV or NVP or LPV/r) or TDF+ 3TC+ EFV from 14 weeks of gestation up to 1-week post cessation of breastfeeding. Infant: NVP at birth (preferably within 72 hours) up to 6 weeks of age. **Transitional Period:** Both Period 1 and Period 2 Regimens (both regimens were in use during this period, due to delayed transition).

https://doi.org/10.1371/journal.pone.0224670.t003
in this age bracket, when compared to those ≤6 weeks of age, also did not receive antiretroviral drugs. Our study demonstrates that mixed-fed infants have significantly higher odds of being HIV positive than formula-fed infants. This could be linked to the lack of ARV prophylaxis cover for a higher proportion of the mixed-fed infants. Mixed feeding is known to disrupt the infant’s intestinal lining, thereby increasing the chances of HIV transmission, especially when there is poor ART coverage, with consequent poor maternal viral load suppression [37]. The adoption of mixed-feeding practice in settings with poor ART coverage and adherence would, therefore, be risky [38].

Overall, our study provided evidence for the effectiveness of PMTCT in service delivery settings, with complexities that are not accounted for by controlled conditions under which efficacy studies are conducted [39–42].

Our study has several limitations: 1) We only reviewed records of HEIs brought by their caregivers for HIV DNA PCR testing, and for whom results were available; the exclusion of non-attendees may have under-estimated the MTCT rate 2). We also did not assess the effect of mode of delivery, maternal CD4+ cell count, viral load, duration of ARVT/P use and adherence on the MTCT rate. Finally, given that the second HIV DNA PCR test results were only

Table 4. Multivariable analysis of the factors associated with MTCT at median age of 8 weeks, using the cumulative pooled data.

| Variable | Crude Odds Ratio | 95% CI | P value | Adjusted Odds Ratio | 95% CI | P value |
|----------|-----------------|--------|---------|---------------------|--------|---------|
| Gender   |                 |        |         |                     |        |         |
| Male     | 1.0             | 1.0    | 1.0     |                     |        |         |
| Female   | 1.3             | 1.0–1.8| 0.096   | 1.2                 | 0.7–1.9| 0.546   |
| Infant Age |             |        |         |                     |        |         |
| ≤6 weeks | 1.0             | 1.0    |         |                     |        |         |
| >6 weeks—2 months | 1.1 | 0.5–2.4 | 0.766 | 0.8 | 0.3–2.1 | 0.636 |
| >2–6 months | 4.0 | 2.2–7.3 | 0.000 | 1.7 | 0.8–3.7 | 0.198 |
| >6–12 months | 8.7 | 4.8–15.8 | 0.000 | 1.8 | 0.8–4.1 | 0.194 |
| >12 months | 25.5 | 12.6–51.4 | 0.000 | **3.3** | 1.2–8.8 | 0.017 |
| **Breastfeeding option** |                 |        |         |                     |        |         |
| Not Breast-fed | 1.0 | 1.0    |         |                     |        |         |
| Exclusively Breast-fed | 1.6 | 1.0–2.6 | 0.056 | 1.9 | 1.0–3.9 | 0.058 |
| Mixed fed   | 5.0             | 3.0–8.4| 0.000   | **2.4**             | 1.1–5.5| 0.032   |
| ART/ARV Prophylaxis Receipt |             |        |         |                     |        |         |
| Both Mother and Infant | 1.0 | 1.0    |         |                     |        |         |
| Mother alone | 3.3 | 1.4–7.7 | 0.008 | **2.8**             | 1.1–7.0| 0.028   |
| Infant alone | 4.3 | 1.4–12.8| 0.010 | **5.6**             | 1.8–17.8| 0.003  |
| Neither Mother, nor Infant | 38.5 | 23.4–63.4 | 0.000 | **26.4**             | 14.0–49.8| 0.000  |
| Hospital |                 |        |         |                     |        |         |
| FMC Yola   | 1.0             | 1.0    |         |                     |        |         |
| SH Yola   | 1.2             | 0.9–1.7| 0.293   | 0.5                 | 0.3–0.8| 0.005   |
| Year |                 |        |         |                     |        |         |
| 2008 | 1.0             | 1.0    |         |                     |        |         |
| 2009 | 1.3             | 0.6–3.1| 0.544   | 1.2                 | 0.3–5.6| 0.794   |
| 2010 | 0.9             | 0.4–2.3| 0.893   | 0.5                 | 0.1–2.1| 0.327   |
| 2011 | 0.6             | 0.3–1.5| 0.275   | 0.3                 | 0.1–1.5| 0.154   |
| 2012 | 0.3             | 0.1–0.9| 0.022   | **0.2**             | 0.0–1.0| 0.049   |
| 2013 | 0.4             | 0.2–1.1| 0.062   | 0.3                 | 0.1–1.6| 0.169   |
| 2014 | 0.3             | 0.1–0.8| 0.021   | 0.2                 | 0.1–1.3| 0.097   |

N = 1,278; Pseudo R²: 37.3%

*Statistically significant odds ratio using pooled data from the two health facilities

*Proportions of mother-infant pair that did not receive ARV/P were 53.7% and 2.1% for HEIs > 12 months and those ≤6 weeks, respectively—analysis restricted to mother-infant pair with information on ARV use for both mother and infant

**Proportions of mother-infant pair that did not receive ARV/P were 37.5%, 10.3% and 4.9% for mixed fed, exclusively breast-fed and HEIs that were not breast-fed, respectively.

https://doi.org/10.1371/journal.pone.0224670.t004
available for 2.7% of the HEIs, our estimates largely assessed MTCT rate at the time of first testing, and not at the final end-point (post-cessation of breastfeeding). However, the strengths of our study lie in: 1) the extensive number of years reviewed. This allowed us to provide evidence on PMTCT effectiveness during two distinct periods of PMTCT protocol implementation, as well as in the transitional period in Nigeria; 2) inclusion of a health facility that provides predominantly secondary-level healthcare services; this level has less specialized health personnel, compared with tertiary or teaching hospitals; 3) our large sample sizes, which were higher than most of the other Nigerian studies.

Conclusion
Our MTCT rate estimates demonstrated the effectiveness of PMTCT interventions in routine settings, as the PMTCT regimens became more intense with earlier initiation of triple therapy. Thus, efforts to scale up lifelong ARVT/P (Option B+) in Nigeria should be accelerated. Given the increased coverage of PMTCT services over the past 16 years, it is important that Nigeria carries out a survey-based population-level evaluation of her PMTCT program, as is done in other countries, like South Africa. This could help in assessing the progress towards Nigeria’s PMTCT targets [3].

Supporting information
S1 Table. ART and PMTCT eligibility criteria and regimens in Nigeria.
(DOCX)
S2 Table. Comparison of Baseline characteristics and prophylaxis status for HIV exposed infants with and without first HIV DNA PCR test results.
(DOCX)
S1 Fig. Flow chart showing the recommended cascade of PMTCT interventions in Nigeria, 2008–2014.
(TIF)
S1 File. Study data.
(XLSX)

Acknowledgments
We would like to thank the Adamawa State Ministry of Health (SMoH) and the management of SH, Yola and FMC Yola, for granting permission to conduct this study. We also appreciate the effort of the healthcare workers, who work tirelessly to ensure that PMTCT services are delivered to clients.

Author Contributions
Conceptualization: Ademola Joshua Itiola, Ameena Ebrahim Goga, Vundli Ramokolo.
Data curation: Ademola Joshua Itiola.
Formal analysis: Ademola Joshua Itiola.
Investigation: Ademola Joshua Itiola.
Methodology: Ademola Joshua Itiola, Ameena Ebrahim Goga, Vundli Ramokolo.
Project administration: Ademola Joshua Itiola.
Resources: Ademola Joshua Itiola.
Software: Ademola Joshua Itiola.
Supervision: Ademola Joshua Itiola, Ameena Ebrahim Goga, Vundli Ramokolo.
Validation: Ademola Joshua Itiola, Ameena Ebrahim Goga, Vundli Ramokolo.
Visualization: Ademola Joshua Itiola.
Writing – original draft: Ademola Joshua Itiola, Ameena Ebrahim Goga, Vundli Ramokolo.
Writing – review & editing: Ademola Joshua Itiola, Ameena Ebrahim Goga, Vundli Ramokolo.

References

1. UNAIDS. Prevention Gap Report. 2016a. Available: http://www.unaids.org/sites/default/files/media_asset/2016-prevention-gap-report_en.pdf. Downloaded: 23.05.2017
2. UNAIDS. HIV and AIDS Estimates. 2015. Available: http://www.unaids.org/en/regionscountries/andcountries/Nigeria Accesssed: 23.05.2017
3. Federal Ministry of Health Nigeria. National Guidelines for Prevention of Mother-to-Child Transmission of HIV (PMTCT). 2010a. Downloaded: http://www.emtct-iatt.org/wp-content/uploads/2013/04/Nigeria_National-PMTCT-Guidelines_2010.pdf Accesssed: 21.08.2013
4. Agboghoroma C, Sagay S, Ikechebelu J. Nigerian Prevention of Mother to Child Transmission of Human Immunodeficiency Virus Program: The Journey So Far. Journal of HIV and Human Reproduction, 2013; 1(1): 1–7.
5. National Agency for the Control of AIDS. PMTCT Demand Creation for Accelerated Uptake of Services: A National Prevention of Mother-to-Child Transmission (PMTCT) of HIV Communication Strategy. Nigeria. 2014. Available: http://sbcvch.naca.gov.ng/sites/default/files/PMTCT%20creation%20strategy.pdf Accesssed: 12.04.2015
6. Khamofu H, Oladele EA, Ralph-Opora U, Badru T, Adebokun O, Saleh M et al. Decline in positivity rates among HIV-exposed infants with changes in the prevention of mother-to-child transmission antiretroviral regimens in Nigeria: Evidence from 7 years of field implementation. J HIV Hum. Reprod. 2015; 3:34–40 Available from: http://www.j-hhr.org/text.asp?2015/3/2/34/186351 Accesssed 12.02.2018
7. Federal Government of Nigeria. Second National Strategic Health Development Plan (2018–2022). 2018
8. UNAIDS. Country Factsheets: Nigeria. 2018. Available from: http://www.unaids.org/en/regionscountries/countries/nigeria/ Accesssed 04.12.2018
9. National Agency for the Control of AIDS. Revised National HIV and AIDS Strategic Framework 2019–2021. 2019. Available from: https://naca.gov.ng/revised-national-hiv-and-aids-strategic-framework-2019-2021/ Accesssed 05.06.2019
10. Ezegbe C, Stephenson N. The Reach and Limits of The US President’s Emergency Plan for AIDS Relief (PEPFAR) Funding of Prevention of Mother-to-Child Transmission (PMTCT) of HIV in Nigeria. African Journal of Reproductive Health. 2012; 16(1):23–34. PMID: 22783665
11. Federal Ministry of Health. National Guidelines for HIV Prevention Treatment and Care. 2016.
12. Federal Ministry of Health. National Guidelines on Prevention of Mother to Child Transmission of HIV (PMTCT). 2007.
13. Agboghoroma CO, Audu LI, Iregbu KC. Effectiveness of Prevention of Mother-to-Child Transmission of HIV Program in Abuja. Journal of HIV & Human Reproduction. 2015; 3(1):7–13. Available: http://www.j-hhr.org/temp/2015/5201927_142659.pdf Accesssed: 05.06.2017
14. Chama C, Gasuah W, Oguche S. The Value of Highly Active Antiretroviral Therapy in the Prevention of Mother-to-Child Transmission of HIV. Journal of Obstetrics and Gynaecology. 2007; 27(2):134–137. https://doi.org/10.1080/01443610601113854 PMID: 17454457
15. Chama CM, Bello M, Ajayi BA, Zarma S, Gasuah W. The Use of Highly Active Antiretroviral Therapy for the Prevention of Mother-to-Child Transmission of the Human Immunodeficiency Virus in Nigeria. Journal of Obstetrics and Gynaecology. 2010; 30(4):362–366. https://doi.org/10.3109/01443611003672104 PMID: 20455718
16. Esene H, Omohigherai AI. Prevalence of HIV among Exposed Infants in University of Benin Teaching Hospital, Benin City, Edo State, Nigeria. Journal of Biomedical Sciences. 2012; 11(1):105–115.
17. Okafor I, Ugwu E, Obi S, Odugu B. Virtual Elimination of Mother-to-Child Transmission of Human Immuno-deficiency Virus in Mothers on Highly Active Antiretroviral Therapy in Enugu, South-Eastern Nigeria. Annals of Medical and Health Sciences Research. 2014; 4(4):615–618. https://doi.org/10.4103/2141-9248.139344 PMID: 25221715

18. Isah AM, Igboeli NU, Adibe MO, Ukwue CV. Evaluation of Prevention of Mother-to-Child Transmission (PMTCT) of HIV in a Tertiary Health Institution in South-Eastern Nigeria. Journal of AIDS and HIV Research. 2016; 8 (8):114–120. Available: http://www.academicjournals.org/JAHR Accessed: 20.09.2016

19. Ale AJ, Adewum N, Emokpa A, Fagorala T, Aruma ED, Abidoye G et al. Outcome of PMTCT Services and Factors Affecting Vertical Transmission of HIV Infection in Lagos, Nigeria. HIV & AIDS Review. 2011; 10(1):14–18.

20. Audu R, Onwuamah C, Salu O, Okwuraiwe A, Ou Chin-Yih BO, Bond KB et al. Development and Implementation Challenges of a Quality Assured HIV Infant Diagnosis Program in Nigeria Using Dried Blood Spots and DNA Polymerase Chain Reaction. AIDS Research and Human Retroviruses. 2014; 31 (4):433–438. Available: 10.06.2017 https://doi.org/10.1089/AID.2014.0159 PMID: 25381805

21. Anoje C, Aiyenigba B, Suzuki C, Badru T, Akpoigbe K, Odo M. et al. Reducing Mother-to-Child Transmission of HIV: Findings from an Early Infant Diagnosis Program in South-South Region of Nigeria. BMC Public Health. 2012; 12(184):1–8.

22. Sagay AS, Edarki AO, Meloni ST, Musa J, Oguche S, Ikewempu CC, et al. Mother-to-Child Transmission Outcomes of HIV-Exposed Infants Followed Up in Jos North-Central Nigeria. Current HIV Research. 2015; 13(3):193–200. PMID: 25986370

23. Kalu S, Reynolds F, Petra G, Ikechebelu J, Dada M, Oluwoyin BO, Bond KB et al. Development and Implementation Challenges of a Quality Assured HIV Infant Diagnosis Program in Nigeria Using Dried Blood Spots and DNA Polymerase Chain Reaction. AIDS Research and Human Retroviruses. 2014; 31 (4):433–438. Available: Accessed: 10.06.2017 https://doi.org/10.1089/AID.2014.0159 PMID: 25381805

24. Newell M. Prevention of Mother-to-Child Transmission of HIV: Challenges for the Current Decade. Bulletin of the World Health Organization. 2001; 79(01): 1138–1144.

25. UNAIDS. The Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. 2016c. Available: http://www.unaids.org/sites/default/files/media_asset/GlobalPlan2016_en.pdf Accessed: 26.12.2018

26. Ale AJ, Adewum N, Emokpa A, Fagorala T, Aruma ED, Abidoye G et al. Outcome of PMTCT Services and Factors Affecting Vertical Transmission of HIV Infection in Lagos, Nigeria. HIV & AIDS Review. 2011; 10(1):14–18.

27. Newell M. Prevention of Mother-to-Child Transmission of HIV: Challenges for the Current Decade. Bulletin of the World Health Organization. 2001; 79(01): 1138–1144.

28. Ikechebelu J, Ugboaja JO, Kalu SO, Ugochukwu EF. The Outcome of Prevention of Mother to Child Transmission Program in a Nigerian Early Infant Diagnosis Centre. Nigerian Journal of Medical Science. 2011; 20(3):204–208. https://doi.org/10.4103/0300-1652.132039 PMID: 25013250

29. Aliyu MH, Blevins M, Megazzini KM, Audet CM, Dunlap J, Sodangi IS et al. Correlates of Sub-optimal Entry into Early Infant Diagnosis in Rural North Central Nigeria. Journal of Acquired Immune Deficiency Syndromes. 2014; 67(1): e19–e26. Available: Accessed: 11.06.2017 https://doi.org/10.1097/QAI.000000000000215 PMID: 24853310

30. Inalegwu A, Phillips S, Datir R, Chime C, Ozumba P, Peters S, et al. Active Tracking of Rejected Dried Blood Samples in a Large Program in Nigeria. World Journal of Virology. 2016; 5(2):73–81. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861873/ Accessed: 12.06.2017 https://doi.org/10.5501/wjv.v5.i2.73 PMID: 27175352

31. Myrti MP, Puttkammer N, Gloyd S, Robinson J, Yuhas K, Domercant JW, et al. ART Attrition across Health Facilities Implementing Option B+ in Haiti. J Int Assoc Provid AIDS Care. 2018; 17:1–10 Available: http://journals.sagepub.com/doi/full/10.1177/1729036X18774037
35. Coetzee D, Hilderbrand K, Boulle A, Draper B, Abdullah F, Goemaere E. Effectiveness of the First District-wide Programme for the Prevention of Mother-to-Child Transmission of HIV in South Africa. Bulletin of the World Health Organization. 2005; 83(7):489–494. PMID: 16175822

36. Torpey K, Mandala J, Kasonde P, Bryan-Mofya G, Bweupe M, Mukundu J. et al. Analysis of HIV Early Infant Diagnosis Data to Estimate Rates of Perinatal HIV Transmission in Zambia. PLoS ONE. 2012; 7(8):e42859 https://doi.org/10.1371/journal.pone.0042859 PMID: 22912752

37. Wise J. Breast Feeding Safer than Mixed Feeding for Babies of Mothers with HIV. British Medical Journal. 2001; 322(7285): 512.

38. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach– 2nd Ed. 2016. Available: http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1 Downloaded: 01.07.2017

39. Goga AE, Dinh TH, Jackson DJ. Evaluation of the Effectiveness of the National Prevention of Mother-to-Child Transmission (PMTCT) Programme Measured at Six Weeks Postpartum in South Africa, 2010. Available: http://www.mrc.ac.za/healthsystems/SAPMTCTE2010.pdf Accessed: 03.06.2013

40. Lussiana C, Clemente SV, Ghelardi A, Lonardi M, Pulido Tarquino IA, Floridia M. Effectiveness of a Prevention of Mother-to-Child HIV Transmission Programme in an Urban Hospital in Angola. PLoS ONE. 2012; 7(4): e36381 https://doi.org/10.1371/journal.pone.0036381 PMID: 22558455

41. Nkwo PO. Prevention of Mother to Child Transmission of Human Immunodeficiency Virus: The Nigerian Perspective. Annals of Medical and Health Sciences Research. 2012; 2(1):56–65. https://doi.org/10.4103/2141-9248.96940 PMID: 23209993

42. Goga A, Jackson D, Lombard C, Ramokolo V, Ngandu N, Sherman G. et al. Highest Risk of Mother To Child Transmission of HIV or Death in the first 6 Months Postpartum: Results from 18 Month Follow-up of an HIV-Exposed National Cohort, South Africa. 2016. Available: http://programme.aids2016.org/Abstract/Abstract/6477 Accessed: 23.06.2017